{"id":"W4281951662","doi":"10.1038/s41375-022-01589-y","title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","year":2022,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Scheme for Promotion of Academic and Research Collaboration; Sun Pharma; National Cancer Institute; Incyte; Jazz Pharmaceuticals; Ariad Pharmaceuticals; Celgene; Gilead Sciences; Pfizer; Daiichi Sankyo Europe; Bristol-Myers Squibb","keywords":"Bosutinib; Imatinib; Medicine; Internal medicine; Cumulative incidence; Adverse effect; Myeloid leukemia; Oncology; Surgery; Nilotinib; Transplantation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00408919,0.0009255343,0.001917511,0.0002631502,0.0002556189,0.0008928564,0.0004175536,0.0007652606,0.002631476],"category_scores_gemma":[0.002115831,0.0002032932,0.002124564,0.000337659,0.0003953797,0.0008755098,0.0003710717,0.001818243,0.0003138943],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005090151,"about_ca_system_score_gemma":0.0005303614,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006688913,"about_ca_topic_score_gemma":0.002310847,"domain_scores_codex":[0.9986083,0.0009451359,0.00007189865,0.000104083,0.0001195322,0.0001511094],"domain_scores_gemma":[0.9984477,0.0005363193,0.0004567079,0.0001039676,0.0001115109,0.0003438572],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9327438,0.002590931,0.008705623,0.0009007319,0.005321539,0.0001187098,0.0000935789,0.00115471,0.003787389,0.0002803684,0.004215788,0.04008687],"study_design_scores_gemma":[0.7267435,0.1616398,0.08948742,0.0003776583,0.007749819,0.0005114285,0.0001742459,0.002498536,0.001695378,0.00063379,0.008398245,0.00009012953],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9770675,0.0159859,0.0004977336,0.0008920499,0.0002132962,0.0003814639,0.002137234,0.00006018801,0.002764657],"genre_scores_gemma":[0.9876425,0.003725075,0.0007216972,0.00122904,0.0004079913,0.0003833384,0.00430072,0.00002115841,0.001568533],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00408919,"threshold_uncertainty_score":0.021626,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05070338452773471,"score_gpt":0.32363280685004,"score_spread":0.2729294223223053,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}